Regkirona market seen growing on personalized medicine and immunocompromised care

The Business Research Company says Regkirona’s market is set to expand through 2035 as COVID-19 treatment demand shifts toward targeted therapies and protection for high-risk patients. North America led in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Regkirona is positioned as a COVID-19 therapy for high-risk patients, making its market tied to demand for early treatment and protection for people who may not respond well to vaccines. - The market outlook points to broader use of monoclonal antibodies in infectious disease care and pandemic preparedness.

What happened: - The Business Research Company published its Regkirona (regdanvimab) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says Regkirona, also known as regdanvimab, is a monoclonal antibody treatment for mild to moderate COVID-19 in high-risk patients. - The report forecasts market trends through 2035 and highlights regional demand patterns. - A free sample is available here. - The full report is available here.

The details: - Regkirona works by binding to the SARS-CoV-2 spike protein, blocking viral entry into human cells and limiting replication. - The report links historical market growth to emergency authorization of COVID-19 antibody therapies, rapid biologics manufacturing scale-up, hospital-based COVID-19 treatment expansion, government procurement, and stronger infectious disease clinical infrastructure. - The report says future growth will be driven by demand for antiviral preparedness, broader monoclonal antibody adoption, more focus on immunocompromised patients, higher pandemic response investment, and next-generation antiviral antibodies. - The report expects trends to include greater reliance on monoclonal antibodies for infectious diseases, earlier COVID-19 interventions, deeper use in hospital protocols, broader pandemic therapeutics, and more focus on high-risk patients. - Personalized medicine is one growth driver, as treatments increasingly align with genetic, environmental, and lifestyle factors. - The report cites a February 2024 Personalized Medicine Coalition update saying the FDA approved 16 new personalized treatments for rare diseases in 2023. - The report also points to rising focus on immunocompromised patients, who may not respond adequately to vaccines and may need passive antibody protection. - CDC data from December 2024 showed about 6% of U.S. adults live with immunocompromising conditions, and that group accounted for 16% of COVID-19 hospitalizations between July 2023 and May 2024. - In 2025, North America was the largest market for Regkirona. - The Asia-Pacific region is projected to grow fastest during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The report frames Regkirona’s opportunity less as a broad pandemic-era drug story and more as a targeted product for defined patient groups. - The emphasis on immunocompromised patients suggests continued commercial relevance even as the COVID-19 market matures. - The regional split signals that the next phase of growth may come from markets outside North America.

What's next: - The Business Research Company expects the market to track broader adoption of monoclonal antibody platforms and pandemic-ready treatment systems. - The report says future demand will depend on continued investment in COVID-19 preparedness and therapies for vulnerable patients. - The company also directs readers to contact its sales and research teams for more information.